Clinical Trials Browser

Phase 1 × parsaclisib × Dermatologic × Clear all

Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT02646748 2022-03-31

Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Clinical Trials

Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas

Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors